{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011612","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.111250+00:00","generated_at":"2026-06-04T05:58:27.648026+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma reports FY2023 net loss of $18.0M; pipeline progress on influenza and COVID-19 programs","bullets":["Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.","Cash at Dec 31, 2023: $26.4M, down from $37.1M; net cash used in ops $14.7M.","FDA provided Pre-IND feedback clarifying requirements for Phase 2b trial of oral CC-42344 for influenza A.","Expect topline data in 2024 from Phase 2a human challenge study with CC-42344 and Phase 1 study with CDI-988.","Plan to initiate Phase 1 study of inhaled CC-42344 in 2024 as influenza treatment/prophylactic."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011612","json":"https://secwatch.observer/filing/0001493152-24-011612.json","markdown":"https://secwatch.observer/filing/0001493152-24-011612.md","text":"https://secwatch.observer/filing/0001493152-24-011612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/0001493152-24-011612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:58:27.648026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4025c7790537deb7a832dfb8907a9ac4da0a78c","claim":"Cocrystal Pharma, Inc. reported financial results for the 12 months ended December 31, 2023.","evidence_excerpt":"Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/0001493152-24-011612-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the 12 months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}